Psoriasis Biosimilars Global Market Report 2025

Description

Psoriasis biosimilars are biologic drugs engineered to closely replicate the structure, function, safety, and efficacy of approved reference biologics used for treating moderate to severe psoriasis. These biosimilars offer a more affordable option compared to original biologics, improving patient access to advanced treatments without compromising quality or clinical outcomes.

The priamry drug classes in psoriasis biosimilars include TNF-alpha inhibitors, infliximab, etanercept, adalimumab, and other biosimilars. TNF-alpha inhibitors are biologics that block tumor necrosis factor-alpha (TNF-a), a protein that drives inflammation in psoriasis. They are applied to various psoriasis types, including plaque, guttate, inverse, and pustular psoriasis, and administered via subcutaneous, intravenous, oral, or topical routes. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The psoriasis biosimilars market research report is one of a series of new reports from The Business Research Company that provides psoriasis biosimilars market statistics, including psoriasis biosimilars industry global market size, regional shares, competitors with a psoriasis biosimilars market share, detailed psoriasis biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the psoriasis biosimilars industry. This psoriasis biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The psoriasis biosimilars market size has grown rapidly in recent years. It will grow from $7.32 billion in 2024 to $8.16 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to the increasing cost burden of original biologics, strong clinical efficacy and safety data of early biosimilar entrants, expansion of approved indications beyond psoriasis, rising prevalence of chronic diseases, and reforms in hospital procurement policies.

The psoriasis biosimilars market size is expected to see rapid growth in the next few years. It will grow to $12.43 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to the rising global incidence of psoriasis, evolving switching policies and interchangeability regulations, expansion of biosimilar manufacturing, enhanced patient and physician education, and the adoption of bundled pricing and value-based contracts. Key trends in the forecast period include innovative biosimilar production platforms, AI-driven patient stratification, the launch of advanced drug delivery devices, development of next-generation formulations, and strategic collaborations within the industry.

The rising diagnosis rates of psoriatic arthritis are expected to drive growth in the psoriasis biosimilars market. Psoriatic arthritis is a chronic autoimmune condition that causes joint and skin inflammation, often affecting individuals with a history of psoriasis. Improved screening protocols have enabled earlier detection and more accurate diagnosis by identifying subtle joint symptoms that previously went unnoticed. Psoriasis biosimilars provide affordable alternatives to biologic therapies, effectively managing joint inflammation and skin symptoms. For instance, in May 2024, according to the National Institutes of Health (NIH), the prevalence of psoriatic arthritis in 2022 was 0.221%, with an incidence rate of 13.54 per 100,000 people. This increasing diagnosis trend is therefore fueling the psoriasis biosimilars market.

Companies in the market are focusing on innovative treatment solutions to improve patient outcomes and accessibility. Biosimilars for plaque psoriasis are lower-cost alternatives to approved biologics that manage chronic autoimmune skin conditions characterized by red, scaly patches. For example, in May 2025, Sandoz Group AG, a Switzerland-based pharmaceutical company, launched the Pyzchiva autoinjector, the first commercially available ustekinumab biosimilar autoinjector. Pyzchiva is approved for adults with plaque psoriasis, psoriatic arthritis, and Crohn's disease, as well as pediatric patients aged six years and older (weighing over 60 kg) with plaque psoriasis. The autoinjector is designed for accurate automatic dosing, reduced injection pain, compact design, and flexible storage, enhancing patient adherence and quality of life.

In September 2023, Sandoz partnered with Samsung Bioepis, a South Korea-based biopharmaceutical company, to commercialize the SB17 (ustekinumab) biosimilar in Europe and North America. This collaboration aims to expand patient access to high-quality, cost-effective immunology treatments while strengthening Sandoz's position in the global biosimilars market.

Major players in the psoriasis biosimilars market are Pfizer Inc., Merck & Co. Inc., Amgen Inc., Biogen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Samsung Bioepis Co. Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Torrent Pharmaceuticals Ltd., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Reliance Life Sciences Pvt. Ltd., and Alvotech hf.

North America was the largest region in the psoriasis biosimilars market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the psoriasis biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The psoriasis biosimilars market consists of sales of tumor necrosis factor inhibitors, monoclonal antibodies, subcutaneous and intravenous formulations, subcutaneous injections, and interleukin inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Psoriasis Biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on psoriasis biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for psoriasis biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The psoriasis biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: TNF-Alpha Inhibitors; Infliximab; Etanercept; Adalimumab; Other Biosimilars
2) By Disease Type: Plaque Psoriasis; Guttate Psoriasis; Inverse Psoriasis; Pustular Psoriasis
3) By Route Of Administration: Subcutaneous; Intravenous; Oral; Topical
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars; Fusion Protein Biosimilars
2) By Infliximab: Remicade Biosimilars; CT-P13 Biosimilars
3) By Etanercept: Enbrel Biosimilars; SB4 Biosimilars
4) By Adalimumab: Humira Biosimilars; ABP 501 Biosimilars
5) By Other Biosimilars: Ustekinumab Biosimilars; Secukinumab Biosimilars
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Amgen Inc.; Biogen Inc.; Sandoz Group AG; Fresenius Kabi AG; Intas Pharmaceuticals Ltd.; STADA Arzneimittel AG; Aurobindo Pharma Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Ltd.; Samsung Bioepis Co. Ltd.; Lupin Ltd.; Zydus Lifesciences Ltd.; Celltrion Inc.; Torrent Pharmaceuticals Ltd.; Bio-Thera Solutions Ltd.; Coherus BioSciences Inc.; mAbxience S.A.; Reliance Life Sciences Pvt. Ltd.; Alvotech hf.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37870

1. Executive Summary

2. Psoriasis Biosimilars Market Characteristics

3. Psoriasis Biosimilars Market Trends And Strategies

4. Psoriasis Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Psoriasis Biosimilars Growth Analysis And Strategic Analysis Framework

5.1. Global Psoriasis Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Psoriasis Biosimilars Market Growth Rate Analysis
5.4. Global Psoriasis Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Psoriasis Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Psoriasis Biosimilars Total Addressable Market (TAM)

6. Psoriasis Biosimilars Market Segmentation

6.1. Global Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
TNF-Alpha Inhibitors
Infliximab
Etanercept
Adalimumab
Other Biosimilars
6.2. Global Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Plaque Psoriasis
Guttate Psoriasis
Inverse Psoriasis
Pustular Psoriasis
6.3. Global Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Subcutaneous
Intravenous
Oral
Topical
6.4. Global Psoriasis Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Psoriasis Biosimilars Market, Sub-Segmentation Of TNF-Alpha Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibody Biosimilars
Fusion Protein Biosimilars
6.6. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Infliximab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Remicade Biosimilars
CT-P13 Biosimilars
6.7. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Etanercept, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enbrel Biosimilars
SB4 Biosimilars
6.8. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Adalimumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Humira Biosimilars
ABP 501 Biosimilars
6.9. Global Psoriasis Biosimilars Market, Sub-Segmentation Of Other Biosimilars, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ustekinumab Biosimilars
Secukinumab Biosimilars

7. Psoriasis Biosimilars Market Regional And Country Analysis

7.1. Global Psoriasis Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Psoriasis Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Psoriasis Biosimilars Market

8.1. Asia-Pacific Psoriasis Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Psoriasis Biosimilars Market

9.1. China Psoriasis Biosimilars Market Overview
9.2. China Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Psoriasis Biosimilars Market

10.1. India Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Psoriasis Biosimilars Market

11.1. Japan Psoriasis Biosimilars Market Overview
11.2. Japan Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Psoriasis Biosimilars Market

12.1. Australia Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Psoriasis Biosimilars Market

13.1. Indonesia Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Psoriasis Biosimilars Market

14.1. South Korea Psoriasis Biosimilars Market Overview
14.2. South Korea Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Psoriasis Biosimilars Market

15.1. Western Europe Psoriasis Biosimilars Market Overview
15.2. Western Europe Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Psoriasis Biosimilars Market

16.1. UK Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Psoriasis Biosimilars Market

17.1. Germany Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Psoriasis Biosimilars Market

18.1. France Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Psoriasis Biosimilars Market

19.1. Italy Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Psoriasis Biosimilars Market

20.1. Spain Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Psoriasis Biosimilars Market

21.1. Eastern Europe Psoriasis Biosimilars Market Overview
21.2. Eastern Europe Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Psoriasis Biosimilars Market

22.1. Russia Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Psoriasis Biosimilars Market

23.1. North America Psoriasis Biosimilars Market Overview
23.2. North America Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Psoriasis Biosimilars Market

24.1. USA Psoriasis Biosimilars Market Overview
24.2. USA Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Psoriasis Biosimilars Market

25.1. Canada Psoriasis Biosimilars Market Overview
25.2. Canada Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Psoriasis Biosimilars Market

26.1. South America Psoriasis Biosimilars Market Overview
26.2. South America Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Psoriasis Biosimilars Market

27.1. Brazil Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Psoriasis Biosimilars Market

28.1. Middle East Psoriasis Biosimilars Market Overview
28.2. Middle East Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Psoriasis Biosimilars Market

29.1. Africa Psoriasis Biosimilars Market Overview
29.2. Africa Psoriasis Biosimilars Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Psoriasis Biosimilars Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Psoriasis Biosimilars Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Psoriasis Biosimilars Market Competitive Landscape And Company Profiles

30.1. Psoriasis Biosimilars Market Competitive Landscape
30.2. Psoriasis Biosimilars Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sandoz Group AG Overview, Products and Services, Strategy and Financial Analysis

31. Psoriasis Biosimilars Market Other Major And Innovative Companies

31.1. Fresenius Kabi AG
31.2. Intas Pharmaceuticals Ltd.
31.3. STADA Arzneimittel AG
31.4. Aurobindo Pharma Ltd.
31.5. Dr. Reddy's Laboratories Ltd.
31.6. Cipla Ltd.
31.7. Samsung Bioepis Co. Ltd.
31.8. Lupin Ltd.
31.9. Zydus Lifesciences Ltd.
31.10. Celltrion Inc.
31.11. Torrent Pharmaceuticals Ltd.
31.12. Bio-Thera Solutions Ltd.
31.13. Coherus BioSciences Inc.
31.14. mAbxience S.A.
31.15. Reliance Life Sciences Pvt. Ltd.

32. Global Psoriasis Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Psoriasis Biosimilars Market

34. Recent Developments In The Psoriasis Biosimilars Market

35. Psoriasis Biosimilars Market High Potential Countries, Segments and Strategies

35.1 Psoriasis Biosimilars Market In 2029 - Countries Offering Most New Opportunities
35.2 Psoriasis Biosimilars Market In 2029 - Segments Offering Most New Opportunities
35.3 Psoriasis Biosimilars Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer